The US FDA Offers $5M Funding for Biosimilar Regulatory Science Pilot Program
Shots:
- The US FDA has provided $5M funding for multiple research proposals under the upcoming BsUFA III regulatory science pilot program which will run from 2023 to 2027
- The program aims is to advance the development of interchangeable products and to make biosimilar development more efficient. Additionally, ~$1M/award per year is available for projects to address the significant issues with the development of biosimilars or interchangeable.
- The US FDA will review the applications from May 2022, while the research projects are expected to start from Sept 2022
Ref: Biosimilar Development | Image: US FDA
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
